DEPARTMENT OF HEALTH & HUMAN SERVICES



Public Het/Ith Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room W066-G609 Silver Spring, MD 20993-0002

Arthrex, Inc. % Ms. Sally Foust Regulatory Affairs Project Manager 1370 Creekside Boulevard Naples, Florida 34108-1945

JAR - 7 1 1

Re: K101823

Trade/Device Name: Arthrex Swivelock Anchors

Regulation Number: 21 CFR 888.3040

Regulation Name: Smooth or threaded metallic bone fixation fastener

Regulatory Class: Class II Product Code: MAI, HWC Dated: January 5, 2011 Received: January 6, 2011

Dear Ms. Foust:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

Page 2 - Ms. Sally Foust

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRIP's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours

Mark N. Melkerson

Director

mo mot Division of Surgical, Orthopedic

and Restorative Devices Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

ATTIMACE STOLK; ARTHREIX SATVELOCK ANCHORS

2 Indications for Use Form

Indications for Use

510(k) Number (if known): K101823

JAN -7 221

Device Name:

Arthrex SwiveLock Anchors

Indications For Use:

The Arthres SwiveLock Anchors are intended for fixation of subre (soft tissue) to bone in the shoulder, foot/ankle, knee, hand/wrist, elbow, and hip in the following procedures:

Shoulder:

Rotator Cuff Repairs, Bankart Repair, SLAP Lesion Repair, Biceps

Tenodesis, Acromio-Clavicular Separation Repair, Dultoid Repair, Capsular

Shift or Capsulolabral Reconstruction,

Foat/Ankle:

Luteral Stabilization, Medial Stabilization, Achilles Tendon Repair, Hallux

Valgus Reconstruction, Mid-foot Reconstruction. Metatarsal Ligament

Repair/Tendon Repair, Borrionectomy.

Knce:

Medial Collateral Ligament Repair, Lateral Collateral Ligament Repair. Patellar Tendon Repair, Posterior Oblique Ligament Repair, Biotibial Band

Tenodesis.

Hand/Wrise:

Scapholunate Ligament Reconstruction, Ulnar or Radial Collateral

Ligament Reconstruction, Radial Collateral Ligament Reconstruction.

Elbow:

Biceps Tendon Reattachment, Tennis Elbow Repair, Ulnar or Radial

Collateral Ligament Reconstruction, Lateral Epicondylitis Repair.

Hip:

Capsular Repair, acetalaular labral repair.

Prescription Use ____ AND/OR Over-The-Counter Use ____ (Per 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

PAGE 1 of 1

M. Malkerson

(Division Sign-Off)

Division of Surgical, Orthopedic,

and Restorative Devices

510(k) Number K10823